Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.58 |
| ▸ | HPGD | P15428 | 3/20 | 0.58 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.58 |
| ▸ | USP2 | O75604 | 1/20 | 0.58 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.58 |
| ▸ | SORT1 | Q99523 | 2/20 | 0.49 |
| ▸ | PPARA | Q07869 | 4/20 | 0.48 |
| ▸ | MRGPRX4 | Q96LA9 | 2/20 | 0.48 |
| ▸ | TAS2R14 | Q9NYV8 | 2/20 | 0.48 |
| ▸ | CFTR | P13569 | 1/20 | 0.47 |
| ▸ | LCK | P06239 | 1/20 | 0.47 |
| ▸ | FYN | P06241 | 1/20 | 0.47 |
| ▸ | CES2 | O00748 | 1/20 | 0.47 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.47 |
| ▸ | PPARD | Q03181 | 1/20 | 0.46 |
| ▸ | PPARG | P37231 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL10978991 | 0.98 | KDM4E (0.56) | KDM4EALDH1A1HPGDHSD17B10USP2 | |
| SCHEMBL3992911 | 0.87 | CFD (0.51) | KDM4EALDH1A1HPGDHSD17B10USP2 | |
| SCHEMBL320173 | 0.86 | CYP2C19 (0.50) | KDM4EALDH1A1HPGDHSD17B10USP2 | |
| SCHEMBL422034 | 0.86 | ALDH1A1 (0.71) | KDM4EALDH1A1HPGDHSD17B10USP2 | |
| SCHEMBL344681 | 0.85 | MAPT (0.48) | KDM4EALDH1A1HPGDHSD17B10USP2 | |
| SCHEMBL4070406 | 0.85 | CFTR (0.62) | KDM4EALDH1A1HPGDPPARAMRGPRX4 | |
| SCHEMBL4638408 | 0.85 | CFTR (0.50) | KDM4EALDH1A1HPGDHSD17B10USP2 | |
| SCHEMBL29617695 | 0.85 | CFTR (0.50) | KDM4EALDH1A1HPGDHSD17B10USP2 | |
| SCHEMBL24750249 | 0.85 | KDM4E (0.54) | KDM4EALDH1A1HPGDHSD17B10USP2 | |
| SCHEMBL29938669 | 0.85 | KDM4E (0.54) | KDM4EALDH1A1HPGDHSD17B10USP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 135 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12630541-B2 | Compounds useful as inhibitors of ALCAT 1 | PERENNA PHARMACEUTICALS, INC. (US) | 2026-05-19 | — | — | US | disclosed |
| EP-4727924-A1 | INHIBITORS OF TREK (TWIK RELATED K+ CHANNELS) CHANNEL FUNCTION | ONO Pharmaceutical Co., Ltd. (JP) | 2026-04-22 | — | — | EP | disclosed |
| US-12576055-B2 | Disease detection and treatment based on trimethyl-lysine levels | THE CLEVELAND CLINIC FOUNDATION (US) | 2026-03-17 | — | — | US | disclosed |
| CN-120136858-A | Compounds useful as ALCAT1 inhibitors | 中美博瑞纳制药有限公司 | 2025-06-13 | — | — | CN | disclosed |
| US-20250171460-A1 | INDUCERS OF KLF2 AND METHODS OF USE THEREOF | RIPARIAN PHARMACEUTICALS, INC. (US) | 2025-05-29 | — | — | US | disclosed |
| CN-110709394-B | Compounds useful as ALCAT1 inhibitors | 中美博瑞纳制药有限公司 | 2025-02-21 | — | — | CN | disclosed |
| WO-2024255743-A1 | INHIBITORS OF TREK (TWIK RELATED K+ CHANNELS) CHANNEL FUNCTION | ONO PHARMACEUTICAL CO., LTD. (JP) | 2024-12-19 | — | — | WO | disclosed |
| EP-4476229-A1 | INDUCERS OF KLF2 AND METHODS OF USE THEREOF | Riparian Pharmaceuticals, Inc. (US) | 2024-12-18 | — | — | EP | disclosed |
| WO-2024243289-A2 | GUT MICROBE DERIVED AROMATIC AMINO ACID METABOLITES FOR DETECTION AND TREATMENT OF DISEASE | THE CLEVELAND CLINIC FOUNDATION (US) | 2024-11-28 | — | — | WO | disclosed |
| CN-118974057-A | KLF2 inducers and methods of use thereof | 里帕里安制药股份有限公司 | 2024-11-15 | — | — | CN | disclosed |
| WO-2007047676-A1 | PYRAZOLE DERIVATIVES, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF USE | MERCK & CO., INC. (US) | 2007-04-26 | — | — | WO | disclosed |
| US-20070088070-A1 | Pyrazole derivatives, compositions containing such compounds and methods of use | PARMEE EMMA R | 2007-04-19 | — | — | US | disclosed |
| WO-2007039175-A1 | N-[1 ,3,4]-THIADIAZOL-2-YL-BENZENE SULFONAMIDES, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS | SANOFI-AVENTIS (DE) | 2007-04-12 | — | — | WO | disclosed |
| US-6153651-A | Ortho-substituted benzoylguanidines, process for their preparation, their use as a medicament or diagnostic, and medicament comprising them | HOECHST AKTIENGESELLSCHAFT (DE) | 2000-11-28 | — | — | US | disclosed |
| EP-0654023-B1 | 5-(2-OXYPHENYL)-PYRROLE DERIVATIVES AS DOPAMINE D3 RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM PLC (GB) | 1998-09-16 | — | — | EP | disclosed |
| EP-0794171-A2 | Orthosubstituted benzoylguanidines, process for their preparation, their use as medicament or diagnostic material and medicaments containing them | HOECHST AKTIENGESELLSCHAFT (DE) | 1997-09-10 | — | — | EP | disclosed |
| US-5523299-A | ADMINISTERING IN TREATMENT OF PSYCHOTIC DISORDERS | SMITHKLINE BEECHAM PLC (GB) | 1996-06-04 | — | — | US | disclosed |
| EP-0654023-A1 | 5-(2-OXYPHENYL)-PYRROLE DERIVATIVES AS DOPAMINE D3 RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM PLC (GB) | 1995-05-24 | — | — | EP | disclosed |
| WO-1994003426-A1 | 5-(2-OXYPHENYL)-PYRROLE DERIVATIVES AS DOPAMINE D3 RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM PLC (GB) | 1994-02-17 | — | — | WO | disclosed |
| US-3953595-A | Substituted benzoic acid hypolipemic agents | PFIZER INC. (US) | 1976-04-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070088070-A1 | Pyrazole derivatives, compositions containing such compounds and methods of use | PC, GOT2, PNLIP | KDM4E 4338/4885ALDH1A1 1729/4885HPGD 152/4885 |
| US-12630541-B2 | Compounds useful as inhibitors of ALCAT 1 | LCLAT1, LPCAT1, ACAT2 | KDM4E 3151/4885ALDH1A1 511/4885HPGD 3466/4885 |
| US-20250171460-A1 | INDUCERS OF KLF2 AND METHODS OF USE THEREOF | SREBF2, LIPG, KLF5 | KDM4E 999/4885ALDH1A1 1828/4885HPGD 662/4885 |
| US-12576055-B2 | Disease detection and treatment based on trimethyl-lysine levels | BHMT, BHMT2, EHMT2 | KDM4E 270/4885ALDH1A1 1296/4885HPGD 3148/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.